[Adaptive servo-ventilation in patients with heart failure and sleep apnea: Insights from the ADVENT-HF trial].
Zhonghua Jie He He Hu Xi Za Zhi
; 47(6): 504-508, 2024 Jun 12.
Article
em Zh
| MEDLINE
| ID: mdl-38858200
ABSTRACT
Heart failure is strongly associated with obstructive and central sleep apnea. The landmark 2015 SERVE-HF trial showed that using adaptive servo-ventilation (ASV) for central sleep apnea (CSA) management was associated with an increased risk of all-cause and cardiovascular mortality among heart failure patients with reduced ejection fractions. Based on the result, the American Academy of Sleep Medicine and the European Society of Cardiology have recommended against the use of ASV for the treatment of CSA in patients with heart failure with an ejection fraction≤45%. Recently, the results from the ADVENT-HF trial have been formally published, indicating that ASV does not increase adverse outcomes and can improve patients' quality of life. Here, we go over these findings in detail.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Apneia do Sono Tipo Central
/
Insuficiência Cardíaca
Limite:
Humans
Idioma:
Zh
Revista:
Zhonghua Jie He He Hu Xi Za Zhi
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China